DelveInsight’s report delivers an in-depth evaluation of chronic rhinosinusitis (CRS) and its subtypes, covering total, diagnosed, gender- and age-specific cases, and treated populations. The report reviews current standards of care and emerging biologics, including DUPIXENT (Regeneron & Sanofi), NUCALA (GSK), and LYR-210/LYR-220 (Lyra Therapeutics). Market forecasts, SWOT analysis,...